Similarly, incorporation of TRAIL, a selective activator of death receptor-mediated apoptosis, into OncoAd.RGD-hTERT yielded OncoAd.RGD-hTERT-TRAIL, which suppressed growth of bladder cancer-initiating cells and inhibited xenograft progression (Yang et al., 2015). Here, TNFSF10 is linked to urinary bladder carcinoma.